Srinivas S, Verma A, Nittala MG, et al. - Researchers examined how monthly 0.3-mg intravitreal ranibizumab injections affect intraretinal hard exudates (HEs) in eyes with diabetic macular edema (DME). Further, they correlate the effect with macular thickness in these eyes. In this randomized, controlled trial, 24 eyes of 24 individuals with DME were randomized to receive monthly intravitreal ranibizumab injections either until macular edema resolved or until both macular edema and HEs resolved. Monthly intravitreal ranibizumab injections led to a significant decrease in intraretinal HEs in eyes with DME that paralleled decreases in macular thickness and volume. They observed worse vision outcomes in correlation to baseline foveal HEs, and no better vision was achieved with continued treatment for persistent HEs in the absence of edema.